| This week's sponsor is CRF Bracket. | | | |
| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. While the playbill of this year's ASCO didn't exactly thrill analysts—or some attendees, according to our executive interviews—we found plenty of buzz-worthy bits. Merck's Keytruda posted a 23.2% five-year survival rate in metastatic lung cancer, unthinkable before the dawn of immunotherapies. Merck then joined AstraZeneca to present promising results from their Lynparza therapy, in notoriously recalcitrant pancreatic cancer. Meanwhile, Amgen unveiled the first clinical data from a KRAS inhibitor—only 30 years in the making—and testing maven Grail showed it could detect and locate a dozen different cancers from one blood draw. Looking ahead, we’ll have CRISPR data on the horizon and a new generation of T-cell therapies promising to be the next big thing, but don’t discount the multitude of combination therapies currently inching through the clinic, either—and we’ll see you in Chicago next year. | |
|
Featured Story | | | Monday, June 3, 2019 The cancer world flocked to Chicago this weekend for the ASCO meeting, traditionally the biggest oncology confab of the year. And though this year's lineup didn't exactly thrill the masses, we found plenty of news, including some data that's so far avoided the spotlight. |
|
|
Top Stories Of The Week Friday, May 31, 2019 It’s that time of year again, when the big and the small come together to shout about (or try to quietly hide) their latest cancer data at the American Society of Clinical Oncology annual meeting. Monday, June 3, 2019 Big Pharma companies are still, naturally, the big spenders in drug R&D, and the numbers are impressive: Last year, and for the first time, the top 15 largest companies (by sales) funneled more than $100 billion into research, and we also saw the FDA approve more drugs than ever before. Saturday, June 1, 2019 CHICAGO—Before the dawn of immunotherapy, long-term survival was almost a foreign concept in the metastatic lung cancer arena. But Saturday, that’s just what Merck showed its Keytruda could produce. Friday, May 31, 2019 New ASCO data from Grail showed its liquid biopsy test not only was able to detect the presence of 12 different kinds of early-stage cancer but could also identify the disease’s location within the body before it spreads using signatures found in the bloodstream. Sunday, June 2, 2019 CHICAGO—AstraZeneca and Merck’s Lynparza is on a roll when it comes to making headlines at the American Society of Clinical Oncology annual meeting—and doing it in some of the toughest-to-treat cancers out there. And it wasn’t going to stop this year. Tuesday, June 4, 2019 The $74 billion deal that will see Bristol-Myers Squibb subsume Celgene into its ranks is all but done, but it’s been a rocky path. Today, Celgene delivered some positive optics for its would-be parent. Monday, June 3, 2019 CHICAGO—It’s been 30 years in the making, but the first clinical data from a KRAS inhibitor is finally here. In a small phase 1 study, Amgen’s prospect, AMG 510, stopped tumor growth in the majority of patients with non-small cell lung and colorectal cancers. Sunday, June 2, 2019 Israeli biotech Ayala Pharmaceuticals has just added $30 million in a Novartis-backed series B round. As preclinical results have shown, the money could be used on clinical testing of its lead drug AL101 in triple-negative breast cancer. Wednesday, June 5, 2019 Humira's had a long run as the world's best-selling drug, but it can't last forever—and now we know which blockbuster will take its place. EvaluatePharma analysts expect Merck's Keytruda to elbow the AbbVie drug aside in 2024 and take the crown. Monday, June 3, 2019 Cadila Healthcare’s U.S. drug manufacturing facility in St. Louis was cited by the FDA for observations in the wake of the company’s Moraiya, India, plant getting tagged by the regulatory agency last month. Resources Sponsored by: AlphaSense What is agile competitive intelligence, and how can it help take market research to the next level? Sponsored by: Reprints Desk, Inc. Get 5 quick tips for faster research and better results! Sponsored by: Blue Latitude Health In this publication, Blue Latitude Health maps the journey of stakeholders impacted by the rise of precision medicine today. Download the report. Sponsored by: Patheon, by Thermo Fisher Scientific Increase Safety & Flexibility with Flow Chemistry Sponsored by: Veeva IONIS shares best practices for implementing an end-to-end RIM solution in this on-demand webinar. Watch now. Sponsored by: WCG Increasingly complex clinical trials place a tremendous burden on study sites, exacerbating already-troubling recruitment and enrollment issues. Overwhelmed, many sites may not be up to the task or have the appropriate infrastructure, creating costly delays that keep new therapies from patients. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Sponsored by: Catalent Download the executive summary to learn key considerations for a successful technology transfer for manufacturing drug products, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Patheon, part of Thermo Fisher Scientific Designed with speed & flexibility,Quick to Clinic™ for Oral Solid Dose helps deliver products to Phase I Clinic in as little as 14 weeks. Sponsored by: Patheon, part of Thermo Fisher Scientific Choosing the Best Sterile Dosage Form for Your Phase I Clinical Supply Needs. |
